-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PJ4LP0moc6BywBHdQxYb4kqjfAOVBRW7R7TxgV4/MuqUPUPgKnhNF73+D99hgJKW
 oXG5CVujvk9pPb4bIPe8ng==

<SEC-DOCUMENT>0001104659-10-047511.txt : 20100907
<SEC-HEADER>0001104659-10-047511.hdr.sgml : 20100906
<ACCEPTANCE-DATETIME>20100907162837
ACCESSION NUMBER:		0001104659-10-047511
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100901
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100907
DATE AS OF CHANGE:		20100907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		101060290

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a10-17003_18k.htm
<DESCRIPTION>8-K
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington,
D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT
TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">SECURITIES
EXCHANGE ACT OF 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date
of report (Date of earliest event reported): <b>September&nbsp;1,
2010</b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact
Name of Registrant as Specified in its Charter)</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-15006</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13-3191702</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State
  or Other Jurisdiction</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission
  File Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS
  Employer</font></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of
  Incorporation)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification
  No.)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">119
  Fourth Avenue</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Needham,
  Massachusetts</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">02494-2725</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address
  of principal executive offices)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip
  Code)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
telephone number, including area code: <b>(781) 433-0771</b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box
below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant
to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17
CFR 240.14d-2(b))</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17
CFR 240.13e-4(c))</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106212\10-17003-1\task4264691\17003-1-ba.htm',USER='106212',CD='Sep  7 23:05 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
1.02. Termination of a Material Definitive Agreement.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
September&nbsp;1, 2010, Pfizer Vaccines, LLC (&#147;Pfizer Vaccines&#148;) provided a
written notice of termination (the &#147;Notice&#148;) with respect to the License and
Development Agreement dated April&nbsp;16, 2008 (&#147;License Agreement&#148;) between
Celldex Therapeutics,&nbsp;Inc. (&#147;Celldex&#148;), and Pfizer Vaccines.&#160; Under the License Agreement, Celldex had
granted to Pfizer Vaccines an exclusive worldwide license to a therapeutic
cancer vaccine candidate, now called rindopepimut, for the treatment of glioblastoma
multiforme and in other potential indications.&#160;
Those rights will be returned to Celldex at the end of a 60-day
transition period.&#160; The Notice was given
under a provision of the License Agreement which permitted termination at any
time and for any reason, upon 60-days&#146; written notice to Celldex.&#160; The Notice did not state a reason for
termination.&#160; However, a Pfizer
spokesperson was quoted in a news article on Bloomberg.com on September&nbsp;3,
2010, as follows: &#147;As part of Pfizer Oncology&#146;s ongoing prioritization of
assets across its broad research and development portfolio, the Company will be
terminating its license and development agreement with Celldex Therapeutics for
the investigational compound rindopepimut.&#148;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
copy of the Celldex press release relating to the above-referenced events is
attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Other Material Relationships with Pfizer Vaccines:&#160; </font></i><font size="2" style="font-size:10.0pt;">Pfizer Vaccines is the
holder of 781,250 shares of Celldex&#146;s common stock.&#160; In addition, the Company entered into a
licensing agreement in December&nbsp;2000 with Pfizer Inc.&#146;s Animal Health
Division (&#147;AHD&#148;) (which we believe to be indirectly affiliated with Pfizer
Vaccines) whereby AHD has licensed certain vaccine technology from the Company
for the development of animal health and food safety vaccines.&#160; The term of the AHD agreement is through the
expiration of the last of the patents covered by that agreement.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Financial
Statements and Exhibits.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits</font></u></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.22%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;Number</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.02%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="85%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:85.76%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.22%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.02%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.76%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press
  Release dated September&nbsp;3, 2010.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_224617_7056"></a></font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106212\10-17003-1\task4264691\17003-1-ba.htm',USER='106212',CD='Sep  7 23:05 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:19.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX
  THERAPEUTICS,&nbsp;INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Avery W. Catlin</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: Avery W. Catlin</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.5%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: Senior Vice
  President / Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated: September&nbsp;7,
2010</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_224712_5335"></a></font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106212\10-17003-1\task4264691\17003-1-ba.htm',USER='106212',CD='Sep  7 23:05 2010' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a10-17003_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>

<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="204" height="76" src="g170031mmi001.jpg" alt="GRAPHIC"></font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE/September&nbsp;3, 2010</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony
  S. Marucci</font></p>
  </td>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.14%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery
  W. Catlin</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">For
  Media:</font></u></p>
  </td>
 </tr>
 <tr>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President
  and CEO</font></p>
  </td>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.14%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief
  Financial Officer</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew
  Driscoll</font></p>
  </td>
 </tr>
 <tr>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex </font><font size="2" style="font-size:10.0pt;">Therapeutics</font><font size="2" style="font-size:10.0pt;">,&nbsp;Inc.</font></p>
  </td>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.14%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex </font><font size="2" style="font-size:10.0pt;">Therapeutics</font><font size="2" style="font-size:10.0pt;">,&nbsp;Inc.</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BMC
  Communications Group</font></p>
  </td>
 </tr>
 <tr>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781)
  433-0771</font></p>
  </td>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.14%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781)
  433-0771</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(212)
  477-9007 x20</font></p>
  </td>
 </tr>
 <tr>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.36%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="38%" valign="top" style="padding:0in 0in 0in 0in;width:38.14%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IR@celldextherapeutics.com</font></p>
  </td>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.5%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">mdriscoll@bmccommunications.com</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS REGAINS WORLDWIDE RIGHTS TO RINDOPEPIMUT (CDX-110)</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;Celldex to Advance Rindopepimut Clinical Program&#151;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;Management to Host Conference Call Today at 8:30 AM Eastern Time&#151;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEEDHAM,
MA (September&nbsp;3, 2010):&#160; </font></b><font size="2" style="font-size:10.0pt;">Celldex
Therapeutics,&nbsp;Inc. (Nasdaq: CLDX) announced today it will regain full
worldwide rights to develop and commercialize rindopepimut (CDX-110), effective
November&nbsp;1, 2010. Celldex and Pfizer Vaccines LLC entered into a global
development and commercialization agreement in April&nbsp;2008 for
rindopepimut, an experimental therapeutic cancer vaccine that targets the
tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII)
in patients with Glioblastoma Multiforme (GBM). Pfizer has informed Celldex
that the rindopepimut program is no longer a strategic priority of Pfizer and
has terminated the agreement. As previously disclosed, across three clinical
studies, rindopepimut has met or exceeded all pre-determined safety and
efficacy objectives.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;There
is a significant need for new therapies for GBM and we are fully committed to
developing rindopepimut for the patients who suffer from this fatal disease,&#148;
said Anthony Marucci, President and Chief Executive Officer of Celldex
Therapeutics. &#147;Importantly, the program has advanced significantly, including
the completion of a multi-center Phase 2 study, the development of a diagnostic
companion product, the manufacture of drug supply for clinical studies, and the
execution of discussions with regulatory agencies on the design of a global
controlled study. We believe the program is very well-positioned to advance
into pivotal clinical studies and that the GBM market remains extremely
attractive.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Rindopepimut
is widely perceived by clinicians as one of the most promising non-toxic drug
candidates for a patient population that has very limited treatment options,&#148;
commented Tom Davis, M.D., Chief Medical Officer of Celldex Therapeutics. &#147;Moving
forward, we remain committed to the brain cancer patient and physician
community and to the continued development of rindopepimut.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#150; more &#150;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">119 FOURTH AVENUE&#160;&#160; NEEDHAM, MA&#160;
02494-2725 USA&#160;&#160; 781-433-0771&#160;&#160; FAX&#160;
781-433-0262</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">www.celldextherapeutics.com</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106212\10-17003-1\task4264691\17003-1-mm.htm',USER='106212',CD='Sep  7 22:56 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rindopepimut
has been studied in three open-label Phase 2 clinical studies in more than 110
patients with GBM confirmed positive for EGFRvIII expression. These studies
consistently demonstrated significant improvements in median-time-to-disease
progression, progression free survival and overall survival, when compared to
historical controls receiving the standard of care. Celldex expects that new
data from the ACT III study will be presented at the 2010 Society for
Neuro-Oncology Scientific Annual Meeting, November&nbsp;18-21, 2010 in
Montreal, Canada. Between today and November&nbsp;1, 2010, Celldex and Pfizer
will work together to transition rindopepimut and related data, intellectual
property and materials from Pfizer Vaccines to Celldex.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Webcast and Conference Call</font></u></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex
will host a conference call and live webcast at 8:30 AM ET on Friday, September&nbsp;3,
2010. The conference call will be webcast live over the Internet and can be
accessed by logging on to the &#147;News&nbsp;&amp; Events&#148; section of the Celldex Therapeutics
website at www.celldextherapeutics.com. The call can also be accessed by
dialing 866.804.6921 (within the United States) or 857.350.1667 (outside the
United States). The passcode for participants is 22193209.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
replay of the call will be available approximately two hours after the live
call concludes through September&nbsp;10, 2010. To access the replay, dial
888-286-8010 (within the United States) or 617-801-6888 (outside the United
States). The passcode is 34127647. The webcast will also be archived on the
Company&#146;s website.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
Celldex Therapeutics,&nbsp;Inc.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex
Therapeutics is the first antibody-based combination immunotherapy company.
Celldex has a pipeline of drug candidates in development for the treatment of
cancer and other difficult-to-treat diseases based on its antibody focused
Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary
portfolio of monoclonal antibodies, antibody-targeted vaccines and
immunomodulators used in optimal combinations to create novel disease-specific
drug candidates. For more information, please visit
http://www.celldextherapeutics.com.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_225208_5796"></a></font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106212\10-17003-1\task4264691\17003-1-mm.htm',USER='106212',CD='Sep  7 22:56 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Safe
Harbor Statement Under the Private Securities Litigation Reform Act of 1995:<i>&#160; </i></font></b><i><font size="2" style="font-size:10.0pt;font-style:italic;">This
release contains </font></i><font size="2" style="font-size:10.0pt;">&#147;<i>forward-looking
statements&#148; made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, including those related to the </i><i>Company&#146;s strategic focus and the future development and
commercialization (by Celldex and others) of rindopepimut (PF-04948568 or
CDX-110), CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127,
Belinostat and other products. Forward-looking statements reflect management&#146;s
current knowledge, assumptions, judgment and expectations regarding future
performance or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance that such
expectations will prove to be correct and you should be aware that actual
results could differ materially from those contained in the forward-looking
statements. Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our need to obtain additional
capital necessary to advance the development of rindopepimut and our other
programs and our ability to obtain such necessary additional capital on
acceptable terms, or at all; our ability to adapt APC Targeting Technology</i></font><i><font size="1" style="font-size:6.5pt;font-style:italic;position:relative;top:-3.0pt;">TM</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">&#160;to develop new, safe and effective vaccines
against oncology and infectious disease indications; our ability to
successfully complete product research and further development of our programs;
our development partners&#146; willingness to make announcements with respect to
co-developed products; the uncertainties inherent in clinical testing; our
ability to manage research and development efforts for multiple products at
varying stages of development; our strategy and business plans concerning the
continued development and commercialization of rindopepimut (PF-04948568 or
CDX-110); our ability to successfully complete the transition of Rindopepimut
from Pfizer to Celldex; the timing, cost and uncertainty of obtaining
regulatory approvals; the failure of the market for the Company&#146;s programs to
continue to develop; our ability to protect the Company&#146;s intellectual
property; the loss of any executive officers or key personnel or consultants;
our ability to successfully integrate the businesses, multiple technologies and
programs of CuraGen and Celldex; competition; changes in the regulatory landscape
or the imposition of regulations that affect the Company&#146;s products; and other
factors listed in our annual report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2009, and its Forms 10-Q and 8-K.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-###-</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_225236_2897"></a></font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106212\10-17003-1\task4264691\17003-1-mm.htm',USER='106212',CD='Sep  7 22:56 2010' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g170031mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g170031mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!,`,P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HH)P,UY[X_^(<OAJ5=.T^V+7LB;_.E4^6JGT_O'^573IRJ2Y8DRDHJ[/0J
M*^6M1\1:SJTIDOM3N9B>QD(4?0#@56M=4U"RE$MK?W4,@_B25@?YUVK+W;XC
MG^M+L?5U%>.^"?BEJ$FH6^EZU&]X)F$<4\29D!_V@/O#WKV*N2K1E2=I&\)J
M:N@KD]<^(WAW0KAK:6Y:XN5.&BMEWE3Z$]`?QK-^)?B6ZTS3H-,TUBM_J#^4
MC+U5>AQ[G(%6?"W@&QT*R0O$DMZPS+.XRQ)Z@9Z"JC",8\\^NR$Y2<N6)07X
MPZ(&'G:=JD*'J[PK@?DU=?HGB/2?$5L9M,O$G"_>7HR?4'D43:/&\94JC`CD
M,H(->8>)-'F\'ZW9^(=!A>,B4)<VT*DJRGV'8\C'KBG%4ZCY4K,3<X:O5'LE
M%0FZB6S%U*XBBV>8S.<!1C//I7#WGQ9T2.Y>#3[6]U%E."T$?RGZ$_X5E"G.
M?PHN4XQW9WU4=8U:VT32Y]0N]_DP+N?8,G&<<#\:YG2?B?H&HWBVEQ]HT^X8
MX47:;5)^O^-+\26/_"':B`>#$/\`T(52I24U&:W$YIQ;B:EQXOTRV\*Q>(I/
M.^PR*K*`GSX8X'%;%E=QW]A;WD.?*GC65-PP<,,C/YUY)K3'_A2&G#/'V>+_
M`-"->E>&I$C\(:2\C!46QB)9C@`;!S55*:C&Z[M"C-MV?8V*0L%ZFN%O_BMH
M5O=-;6,-WJ,BG!-M'E?P-26'Q$T?6Y198N+&]8X6&Z39O/H#T)J70J)7:&JD
M&[7-[P[XGT_Q/;W$VG^;L@E\I_,3;S[5LUYI\&O^01J^?^?T_P`JZ/Q%X_T/
MPW/]FN)GGO/^?>W7>P^OI55*3]HX05Q0G[BE(ZBBO/8_BYI:.OVW2]3M8F/$
MCQ9'UKM=/U:QU:P6^L+E+BW;HR'OZ$=C[&HG2G#62*C.,MF7:*S-/UZQU*ZD
MM8F=)X_O1R+M/OBM%W6-&=V"JHR6)P`*R3OL.,E)70ZBN?T/QCI7B*_N+73/
MM$WV?.^;RL1_@WO7054HN+LP33U1B>)M5;3=+D>,XE;Y4^IK`W:3X]TG^RM7
MC6.]49BD7@@_WD/\Q1XY<E8%SQO/\JXU':-U=&*LIR&!P0:Q=64)W1P5Z\H5
M;=#CO$WA?4/"NI&UO4W1MDPSJ/DD']#ZBLW3]/N]5OXK*Q@::YE.%1?YGT'O
M7O<$EOXK\(7-OK4*2[`RANAR%R&'H:R/AO!8Z3X#.KPP(VH3([R.W5MI.%]A
M7L0QUZ/.UJ-4XR::>CU+&@>'-+^'>F"\O2ESK$JXR.W^RGH/4UN^%O$$VL?:
MX[G:)4.]0HP`I[?A7G]Y>W&H737-S(7D;OV`]![5O>!RPU]E'W6@;/YBO'E7
ME4J79%/$-U5&.B,KQ:V_XJ^'!-CR=R]>F=Q_^M7KM>8_$G0KJZA@U*P5C>6#
M^:H4<E>O'N"`:Z7PEXXTSQ-I\9\^.&_50)K=V`8-W(SU%=TTYTHR731G9%\L
MVGU.IJI<BV@_TB>6.%0<;W8*/S-3R3PPH7DE1%'5F8`5Y+XPU<^/-<M/#&BO
MYUJDHDNKA/N#'OZ#G\<5G2I\[\NI<Y\J\RU\6-9+6^G:2ER(K:[DWSR@Y'EC
M'IU'.:O:5XC\!Z/81VEIJUO$BC!*HV6/J3CDUD_$G36LUTK4X8!+#ISJLD9&
M1Y?&,CTX_6NNTC3_``]KMA'>:?;V$L3C.!$F4/H1C@BMGR^QC>]M=C-<WM&<
MGXKUGP9KVES0'5+>28(3#+L.Y&[<XZ=JIP:O-JWP:NOM#EY;4&W+$Y)`*[?T
M./PKJ_$Z>'O#6ERW=U:6)E`_=0>4NZ1NPQC]:R=::2;X67%S+IL&G//%YGV>
M$8`!88)]R*J#7+%).UUN*2=W=]#-UK_DB.F_]>\7_H1J7QCJMS'\/O#FDVKE
M&U"&&)B.ZA%X_,BHM:_Y(CIO_7O%_P"A&F^+;&XD\#^'M2MU+/80PS$#^[L7
M)_,"KA;F5_YF3*]G;LCT/0/"=GH6F16MO&JL%'F.!\SMW)-4O%?AN'5=->&1
M`90,PS8^:-QT(/UK8\/>(;#Q'I4-Y9S(Q91YD>?FC;N"*I>,?$-EH6E/)-*K
M7+#;!`IR[N>@`KC7M/:?WC?W>7R//_AYJ;Z+X$\0WG66"5F&>[!/\:K>!-2\
M+6%M)J6MZI%_;%Q(S.TJEF09[''4]:?X#L7U3P-KUH>'GF*_1BO^-7OAT=(O
M-/;1M1M[2/5;21D9)XUW2#/;/4CI7;4M^\]5>W8YX7]TW+SQGX-G@:-M8MY4
M889'1B#^!%<SX%U"RL_B!=Z7I-T)=)OXBZ*,X1P,]_3D?3%>AS^'=(MX6EGM
M+".-1DL\2`#\<5@>#M3L]6\37RZ9H]HNG6?RKJ"H`SMZ+Q]?PK"#CR2Y4[6[
MFDD^979<US2ITN%OK0E+R([@P_BQ_6N?\1ZKKWB^*RT338O(BGXO90?NX['N
M%[^_2K'CSQ1/?:@OA;P^/-OYCMGE0_ZH=QGU]3VI\>B7WAZVM;FWN'FN[9`)
M6;_EH._X=JQY71M5[]/U,JBM)N&W4[/PWH%IX<TB*QM$PJ\LQZNW=C[UL5G:
M-J\&LV*SQ'#CB2//*&M&LW+FU.J+3BG'8Y'QA9-/:EE!+(=PK@*]BOK47,)&
M.:\^U+P^\-\K1IF)I!O3T&><5C5@WJCCQ=!R?/$BL;S[+H$@SC>\G_H-9W@R
M\_XHZ.US_P`L9>/Q-4-3UF,K):0PI#%$[XVL3N[<Y^E97AO5OL&GP_(L@"LI
M1B0"#]*]6GAY+#\CW_X<(KE2CY&R.E=MX"L&!N+]Q@,/+3W]36/IVA-K$MO-
M#&(;22)78@YY[@9KT>RM8[*U2")0J(,`"O*A3<9:]",-AY*?-+H%S:K.OOV-
M</K/PXTG4[@W#6[P3DY,MLVPD^N.E>@45T1G*#O%V/0E%2T9Y9'\*+.1\7&H
M:C+'G[C2\?C7<Z!X:T[P_;>38VR1`_>(Y9OJ>IK:Q153JSFK29,81CLBA?Z>
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M=YCC,BI'L&%P>I[FH='UB\?4HHI[B26*6`R8D51S_L@=!]:MXF;5FV2G3NGR
M[E[0/"MCX?L;BVLUD"SR>8^]MWS5CZ]X!TW6KCSYX7CN1TG@;8_X^M.36[];
M9KXWX9DN?*^S;!AEW8QZYJ?4M:OCJ-XEO,8DM@NQ0$VL2,DON.<?2I5>2?-?
M4'4ARVL8,7PKLI'`NK_4[B(?\LY)_E-=K;Z-;Z9HYT_3T%K'M*KY7!4GN#Z^
M]5FUF4:@R/(D<9L?.VDCA_K67=W=S>VNAS27#(S2H68`=3WISKSEN[AS0C?E
M1:\,>#]*\/7-P]N6DNY?FD>9]TF/\":Z&[M%G3@?-6#+J<EMJ^HNJJYCLPZ_
M*,D^Y]*?IM_<J\#S:FEQY\'F-"5`*GU7';ZU,JCD[LN,TGRI%C2]!AL-0>[B
M,D;MG<BM\C?A6[7(Z-K%[+JD"75TS+.7"@*K1MCD;2.1P.]==2BU;0=)Q:]U
M6"JMU91W"X(YJU15&ARS>"M,9B38VY)Z_NQS21>"-(CP!I]J%'81"NJHJN>7
M<5D5K.R@L;=(8(ECC0855&`*LT45(PHHHH`****`"BBB@!DJ>8A%41I-L!*/
M(C_>_P"L^7[_`-?6M&B@3290.F1;@XC4.%V!L<A?3Z5%;Z+:V\C2QP1I(W5E
M7!K4HHL%D4?[.A2V,,<:(C$DJ!P2>M4HM!M;8B2*VC61<[6"\BMNBE9!RKL8
M-AX<MK<[WC224.7$C*,C)JQ)HEK/<"6:".1EZ%ES6M119"4(I6L95QHUO=2H
MTT,<FW[NY<XJ1])MI(DA:"-HDQM0KP,>E:-%%D/E78SSIL7F-*(U$C#:6QR1
MZ4RWT>VM=[0V\<;OU*K@FM.BG8+(S++1K6TN3<);QK*<_,%YK3HHH!)+8__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
